Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:LIFE)

1.900 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about aTyr Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real. 
Via InvestorPlace
LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024
LIFE stock results show that aTyr Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while. 
Via InvestorPlace
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023
LIFE stock results show that aTyr Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Recap: aTyr Pharma Q4 Earnings
Via Benzinga
aTyr Pharma's Earnings Outlook
Via Benzinga
Analyst Expectations for aTyr Pharma's Future
Via Benzinga
The Latest Analyst Ratings for aTyr Pharma
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
aTyr Pharma: Q1 Earnings Insights
Via Benzinga
Where aTyr Pharma Stands With Analysts
Via Benzinga
aTyr Pharma's Earnings: A Preview
Via Benzinga
The 3 Best Penny Stocks to Buy in February 2024
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies. 
Via InvestorPlace
$12M Bet On This Trucking Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks... 
Via Benzinga
aTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer Analyst
Oppenheimer has downgraded aTyr Pharma Inc (NASDAQ: LIFE) to Perform from Outperform, citing a few material catalysts in the next few quarters. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023
Bard AI has consistently outperformed, and it has identified seven growth stocks that it believes will deliver triple-digit returns. 
Via InvestorPlace
3 Stocks and Cryptos With the Highest Potential Returns
If you're only worried about upside, these stocks and cryptos have some of the highest possible returns in the market. 
Via InvestorPlace
7 Hot Growth Stocks Poised to Triple in 2023
These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher. 
Via InvestorPlace
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off another day of trading with a look at the biggest pre-market stock movers investors need to watch for Wednesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
This Company Is Beginning A Pivotal Phase 3 EFZO-FIT™ Study. Could It Be A Much-Needed Treatment For Pulmonary Sarcoidosis?
Most people may never have heard of sarcoidosis, an inflammatory disease that affects about 1.2 million people worldwide.  
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 64 companies achieved new lows for the year. 
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.